The reported radiographic response rates in patients with non-small-cell lung cancer with EGFR exon 20 insertion mutations range from less than 15% for poziotinib to close to 30% for mobocertinib but the duration of response can exceed 15 months [8,10,15,17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.